CN Patent

CN104945420A — 作为pi3k抑制剂的嘧啶酮类

Assigned to Because of C1-esteraseremmer-N parent corporation · Expires 2015-09-30 · 11y expired

What this patent protects

本发明提供了调节磷酸肌醇3-激酶(PI3K)的活性并且可用于治疗与PI3K活性有关的疾病的作为PI3K抑制剂的嘧啶酮类，所述疾病包括例如，炎性障碍、免疫障碍、癌症和其它疾病。

USPTO Abstract

本发明提供了调节磷酸肌醇3-激酶(PI3K)的活性并且可用于治疗与PI3K活性有关的疾病的作为PI3K抑制剂的嘧啶酮类，所述疾病包括例如，炎性障碍、免疫障碍、癌症和其它疾病。

Drugs covered by this patent

ruxolitinib-phosphate (RUXOLITINIB PHOSPHATE)

Patent Metadata

Patent number: CN104945420A
Jurisdiction: CN
Classification: —
Expires: 2015-09-30
Drug substance claim: No
Drug product claim: No
Assignee: Because of C1-esteraseremmer-N parent corporation
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.